Browse > Article
http://dx.doi.org/10.4333/KPS.2009.39.3.207

The Bioequivalence of Plunazol Tablet (Fluconazole 150 mg) to Three capsules of Diflucan 50 mg  

Chang, Hee-Chul (Life Science Research Institute, Daewoong Pharm. Co. Ltd.)
Lee, Min-Suk (Life Science Research Institute, Daewoong Pharm. Co. Ltd.)
Ryu, Chong-Hyon (Life Science Research Institute, Daewoong Pharm. Co. Ltd.)
Lyu, Seung-Hyo (Life Science Research Institute, Daewoong Pharm. Co. Ltd.)
Cho, Sang-Heon (Department of Clinical Pharmacology and Therapeutics, ASAN Medical Center)
Choi, Yeon-Jin (Department of Clinical Pharmacology and Therapeutics, ASAN Medical Center)
Hwang, Ae-Kyung (Department of Clinical Pharmacology and Therapeutics, ASAN Medical Center)
Kim, Yun-Ah (Department of Clinical Pharmacology and Therapeutics, ASAN Medical Center)
Park, Si-Hyun (Department of Clinical Pharmacology and Therapeutics, ASAN Medical Center)
Yoon, Ji-Won (Department of Clinical Pharmacology and Therapeutics, ASAN Medical Center)
Bae, Kyun-Seop (Department of Clinical Pharmacology and Therapeutics, ASAN Medical Center)
Publication Information
Journal of Pharmaceutical Investigation / v.39, no.3, 2009 , pp. 207-216 More about this Journal
Abstract
Fluconazole is used as an orally administrated antifungal drug for the treatment of tinea corporis, candidiasis including skin mycotic pneumonia infections. The dosage of fluconazole varies with indication ranging from 50 mg/day to 400 mg/day. The fluconazole capsule 50 mg (3 capsules daily) is already available in Korean market. To improve the patient compliance, a fluconazole tablet 150 mg (once a day administration) was developed recently. The purpose of this study was to evaluate the bioequivalence of three doses of fluconazole capsule 50 mg (Diflucan 50 mg, Pfizer Korea Inc., as a reference drug) and a single dose of fluconazole tablet 150 mg (Plunazol 150 mg, Daewoong Pharm. Co., Korea) according to the guidelines of the Korea Food and Drug Administration (KFDA). The bioequivalence for three capsules of Diflucan 50 mg and a single tablet of Plunazol 150 mg was investigated in twenty-four healthy male volunteers under a randomized 2${\times}$2 crossover trial design. The average age of twenty-four volunteers was 24.78${\pm}$3.27 year-old, average height was 175.56${\pm}$5.45 cm and average weight was 67.24${\pm}$6.86 kg. After three capsules of Diflucan 50 mg or a single tablet of Plunazol 150 mg were orally administered, blood was taken at predetermined time intervals and the plasma concentrations of fluconazole in plasma were determined using LC-MS-MS. The 90% confidence intervals for the main parameters of statistical results after logarithmic transformation were AUCt 0.9272-1.0084 and Cmax 0.8423-0.9544 respectively, which are in the range of log 0.8 to log 1.25 and the statistical results of additional parameters (AUClast, t1/2 and MRT) were also in the 90% confidence interval that is in the range of log 0.8 to log 1.25. Therefore, the results of this study confirm the bioequivalence of three capsules of Diflucan 50 mg to one tablet of Plunazol 150 mg.
Keywords
fluconazole; Diflucan; Plunazol; bioequivalence; LC-MS-MS;
Citations & Related Records
연도 인용수 순위
  • Reference
1 S. Jevons, L. Lees and M.H. Tarbit, Early clinical experience with UK-49,858 in human volunteers and patients. (abstract #S-64-3) 14th International Congress of Chemotherapy, Kyoto, 23-28, June (1985)
2 H. Washton, Review of fluconazole: a new triazole antifungal agent, Diagn. Microbiol. Infect. Dis. 12 (4 Suppl.), 229-233 (1989)   DOI   ScienceOn
3 M. Nakashima, The clinical study of fluconazole against pulmonary mycosis. Effects of fluconazole on pulmonary cryptococcosis and aspergillosis, and its pharmacokinetics in patients, Jpn. J. Antibiot. 42 (1), 127-137 (1989)   DOI
4 Diflucan drug information. Pfizer. Available at: www.pfizer.com
5 S.M. Grant and S.P. Clissold, Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses, Drugs, 39 (6), 877-916 (1990)   DOI   ScienceOn
6 식품의약품안전청 고시 제 2005-31호, 생물학적동등성시험기준 (2005.6.7)
7 K. Shiba, A. Saito and T. Miyahara, Pharmacokinetic evaluation of fluconazole in healthy volunteers, Jpn. J. Antibiot., 42 (1),17-30 Jan (1989)
8 식품의약품안전청 고시 제 1999-67호, 의약품임상시험관리기준 (2000.1.4)
9 R. Peireira, S. Fidelis, M.L. Vanunci, C.H. Oliveira, G.D. Mendes, E. Abib and R.A. Moreno, Bioequivalence study of two Fluconazole capsule formulations in healthy volunteers. Int. J. Clin. Pharmacol. & Ther., 42 (1), 39-42 (2004)
10 L.A. Moraes, F.E. Lerner, M.E. Moraes, M.O. Moraes, G. Corso and G. De Nucci, Fluconazole Bioequivalence Study:Quantification by Tandem Mass Spectroscopy. Ther Drug Monit., 21, 200-207 (1999)   DOI   ScienceOn
11 M.G. Rinaldi, P.A. Robinson, J.R. Graybill, J.J. Stern and A.M. Sugar, Fluconazole concentrations in patients undergoing antifungal therapy. 28th ICAAC, Los Angeles, abstract no.66, pp. 23-26, Oct. (1988)